Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Recommendation of “Moderate Buy” by Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has been assigned an average recommendation of “Moderate Buy” from the sixteen research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $203.5714.

A number of research firms recently weighed in on CRL. Citigroup lifted their target price on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Barclays cut their price target on Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, February 19th. Bank of America upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective on the stock in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Finally, Robert W. Baird set a $193.00 target price on Charles River Laboratories International in a research report on Thursday, February 19th.

Charles River Laboratories International Price Performance

NYSE CRL opened at $157.24 on Friday. Charles River Laboratories International has a 12 month low of $91.86 and a 12 month high of $228.88. The stock has a market cap of $7.74 billion, a price-to-earnings ratio of -53.12, a PEG ratio of 2.63 and a beta of 1.64. The company’s 50 day moving average is $188.02 and its two-hundred day moving average is $180.82. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. The business had revenue of $994.23 million during the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The company’s revenue was down .8% on a year-over-year basis. During the same period in the prior year, the business posted $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, research analysts anticipate that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

A number of institutional investors have recently added to or reduced their stakes in CRL. Tema Etfs LLC purchased a new position in shares of Charles River Laboratories International in the fourth quarter worth $26,000. Neo Ivy Capital Management bought a new position in shares of Charles River Laboratories International during the second quarter worth $29,000. Rothschild Investment LLC grew its stake in Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares in the last quarter. Atlantic Union Bankshares Corp purchased a new position in Charles River Laboratories International during the third quarter valued at $31,000. Finally, Los Angeles Capital Management LLC bought a new stake in Charles River Laboratories International in the 4th quarter valued at $42,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.